Helen Katrina Tayton-martin, Chief Business Officer at Adaptimmune Therapeutics PLC (ADAP), sold 200,000 shares at $8.74 ($1.7M) on 2020-08-03, disclosed to the SEC on 2020-08-04.
Open-market sale of $1.7M ADAP by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.